Sulforaphene inhibits the progression of osteosarcoma via regulating FSTL1/NF-κB pathway

Area of Science:

• Oncology
• Molecular Biology
• Natural Products Chemistry

Background:

• Osteosarcoma is a primary bone malignancy with limited treatment options.
• Sulforaphene (SFE), an isothiocyanate from cruciferous vegetables, shows potential anti-cancer properties.
• Understanding SFE's mechanism in osteosarcoma is crucial for therapeutic development.

Purpose of the Study:

• To investigate the therapeutic effects of SFE on osteosarcoma progression.
• To elucidate the underlying molecular mechanisms of SFE action in osteosarcoma cells.
• To evaluate the in vivo efficacy of SFE in osteosarcoma xenografts.

Main Methods:

• Cell proliferation, apoptosis, migration, and invasion assays were performed on osteosarcoma cells (U2OS, Saos2) treated with SFE.
• Western blot analysis was used to assess protein expression levels of FSTL1 and NF-κB.
• In vivo tumor xenograft models in nude mice were utilized to evaluate SFE's anti-tumorigenic effects.

Main Results:

• SFE demonstrated dose-dependent inhibition of osteosarcoma cell growth and promotion of apoptosis.
• SFE significantly reduced the expression of both FSTL1 and NF-κB.
• Interfering with FSTL1 or NF-κB diminished the anti-cancer effects of SFE, highlighting their role in SFE's mechanism.

Conclusions:

• SFE effectively alleviates osteosarcoma progression by targeting the FSTL1/NF-κB signaling pathway.
• This study identifies SFE as a promising agent for osteosarcoma treatment.
• Modulating the FSTL1/NF-κB pathway is a key mechanism through which SFE exerts its anti-osteosarcoma effects.